The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378898167 | ||
| 003 | CHVBK | ||
| 005 | 20180305123511.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20041201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2004.254 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2004.254 | ||
| 245 | 0 | 4 | |a The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk |h [Elektronische Daten] |c [Göran Walldius, Ingmar Jungner, Are H. Aastveit, Ingar Holme, Curt D. Furberg, Allan D. Sniderman] |
| 520 | 3 | |a Background: The apolipoprotein B (apoB)/apoA-I ratio represents the balance of proatherogenic and antiatherogenic lipoproteins. The purpose of this study was to determine whether the apoB/apoA-I ratio was superior to any of the cholesterol ratios - total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C), low-density lipoprotein cholesterol (LDL-C)/HDL-C and non-HDL-C/HDL-C - in predicting the risk of coronary disease. Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio. Methods: Plasma lipids, lipoproteins, apoB, and apoA-I were measured in 69,030 men and 57,168 women above 40years of age. After a mean follow-up of 98months, 1183 men and 560 women had died from a myocardial infarction in this prospective apolipoprotein-related mortality risk (AMORIS) study. Results: High apoB and a high apoB/apoA-I ratio were strongly related to increased coronary risk, while high apoA-I was inversely related to risk. The apoB/apoA-I ratio was superior to any of the cholesterol ratios in predicting risk. This advantage was most pronounced in subjects with LDL-C levels <3.6mmol/l. Addition of lipids, lipoproteins or any cholesterol ratio to apoB/apoA-I in risk models did not further improve the strong predictive value of apoB/apoA-I. Conclusions: These results indicate that the apoB/apoA-I ratio is at present the best single lipoprotein-related variable to quantitate coronary risk. Given the additional advantages apolipoproteins possess - fasting samples are not required, apoB/apoA-I is a better index of the adequacy of statin therapy than LDL-C, and the measurement of apoB and apoA-I are standardized, whereas LDL-C and HDL-C are not - there would appear to be considerable advantage to integrating apolipoproteins into clinical practice. | |
| 540 | |a ©2004 by Walter de Gruyter Berlin New York | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 690 | 7 | |a apolipoprotein A-I |2 nationallicence | |
| 690 | 7 | |a apolipoprotein B |2 nationallicence | |
| 690 | 7 | |a fatal myocardial infarction |2 nationallicence | |
| 690 | 7 | |a guidelines |2 nationallicence | |
| 690 | 7 | |a lipoproteins |2 nationallicence | |
| 700 | 1 | |a Walldius |D Göran |u King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden and AstraZeneca, Molndal, Sweden |4 aut | |
| 700 | 1 | |a Jungner |D Ingmar |u CALAB Research, Stockholm and Karolinska Institute, Stockholm, Sweden |4 aut | |
| 700 | 1 | |a Aastveit |D Are H. |u Department of Chemistry, Biotechnology and Food Science, Agricultural University of Norway, As, Norway |4 aut | |
| 700 | 1 | |a Holme |D Ingar |u Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway |4 aut | |
| 700 | 1 | |a Furberg |D Curt D. |u Wake Forest University School of Medicine, Winston-Salem, NC, USA |4 aut | |
| 700 | 1 | |a Sniderman |D Allan D. |u Mike Rosenblom Laboratory for Cardiovascular Research, McGill University Health Center, McGill University, Montreal, QC, Canada |4 aut | |
| 773 | 0 | |t Clinical Chemical Laboratory Medicine |d Walter de Gruyter |g 42/12(2004-12-01), 1355-1363 |x 1434-6621 |q 42:12<1355 |1 2004 |2 42 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2004.254 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2004.254 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Walldius |D Göran |u King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden and AstraZeneca, Molndal, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Jungner |D Ingmar |u CALAB Research, Stockholm and Karolinska Institute, Stockholm, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Aastveit |D Are H. |u Department of Chemistry, Biotechnology and Food Science, Agricultural University of Norway, As, Norway |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Holme |D Ingar |u Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Furberg |D Curt D. |u Wake Forest University School of Medicine, Winston-Salem, NC, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sniderman |D Allan D. |u Mike Rosenblom Laboratory for Cardiovascular Research, McGill University Health Center, McGill University, Montreal, QC, Canada |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemical Laboratory Medicine |d Walter de Gruyter |g 42/12(2004-12-01), 1355-1363 |x 1434-6621 |q 42:12<1355 |1 2004 |2 42 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||